恩夫韦肽和西夫韦肽联合应用的协同疗效，这两种药物分别为第一代和第二代 HIV 融合抑制剂。
Synergistic efficacy of combination of enfuvirtide and sifuvirtide, the first- and next-generation HIV-fusion inhibitors.
机构信息
Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA.
出版信息
AIDS. 2009 Mar 13;23(5):639-41. doi: 10.1097/QAD.0b013e328325a4cd.
Abstract
Enfuvirtide and sifuvirtide, the first- and next-generation HIV-fusion inhibitors, contain different functional domains and have distinct target sites. Here, we found that a combination of enfuvirtide and sifuvirtide resulted in potent synergism in inhibiting HIV-1-mediated cell-cell fusion and infection by X4 and R5 as well as enfuvirtide-resistant HIV-1 strains. These findings suggest that application of enfuvirtide and sifuvirtide in combination may improve their efficacy and resistant profile, leading to a reduction of the dosage and frequency of drug use.
摘要
恩夫韦肽和西夫韦肽是第一代和第二代 HIV 融合抑制剂，它们包含不同的功能域，具有不同的靶位。在这里，我们发现恩夫韦肽和西夫韦肽联合使用可显著增强抑制 X4 和 R5 型 HIV-1 介导的细胞-细胞融合和感染以及对恩夫韦肽耐药的 HIV-1 株的作用。这些发现提示，联合应用恩夫韦肽和西夫韦肽可能会提高它们的疗效和耐药谱，减少用药剂量和频率。
相似文献
1
Synergistic efficacy of combination of enfuvirtide and sifuvirtide, the first- and next-generation HIV-fusion inhibitors.
AIDS. 2009 Mar 13;23(5):639-41. doi: 10.1097/QAD.0b013e328325a4cd.
2
Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect against enfuvirtide- sensitive and -resistant HIV type 1 strains.
J Virol. 2009 Aug;83(16):7862-72. doi: 10.1128/JVI.00168-09. Epub 2009 Jun 3.
3
The improved efficacy of Sifuvirtide compared with enfuvirtide might be related to its selectivity for the rigid biomembrane, as determined through surface plasmon resonance.
PLoS One. 2017 Feb 16;12(2):e0171567. doi: 10.1371/journal.pone.0171567. eCollection 2017.
4
Mechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 Pocket.
J Virol. 2015 Jun;89(11):5801-11. doi: 10.1128/JVI.00373-15. Epub 2015 Mar 18.
5
In vitro selection and characterization of HIV-1 variants with increased resistance to sifuvirtide, a novel HIV-1 fusion inhibitor.
J Biol Chem. 2011 Feb 4;286(5):3277-87. doi: 10.1074/jbc.M110.199323. Epub 2010 Nov 23.
6
The rare HIV-1 gp41 mutations 43T and 50V elevate enfuvirtide resistance levels of common enfuvirtide resistance mutations that did not impact susceptibility to sifuvirtide.
Antiviral Res. 2010 Jun;86(3):253-60. doi: 10.1016/j.antiviral.2010.03.003. Epub 2010 Mar 21.
7
HIV-1 gp41-targeting fusion inhibitory peptides enhance the gp120-targeting protein-mediated inactivation of HIV-1 virions.
Emerg Microbes Infect. 2017 Jun 21;6(6):e59. doi: 10.1038/emi.2017.46.
8
[The current progress in the development of HIV-1 fusion inhibitors].
Yao Xue Xue Bao. 2010 Feb;45(2):184-93.
9
Resistance to enfuvirtide, the first HIV fusion inhibitor.
J Antimicrob Chemother. 2004 Aug;54(2):333-40. doi: 10.1093/jac/dkh330. Epub 2004 Jul 1.
10
Synthesized peptide inhibitors of HIV-1 gp41-dependent membrane fusion.
Curr Pharm Des. 2013;19(10):1800-9. doi: 10.2174/1381612811319100004.
引用本文的文献
1
ADS-J21 is a novel HIV-1 entry inhibitor targeting gp41.
Curr Res Microb Sci. 2024 Jul 9;7:100260. doi: 10.1016/j.crmicr.2024.100260. eCollection 2024.
2
Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41.
Viruses. 2019 Aug 1;11(8):705. doi: 10.3390/v11080705.
3
Combining a Fusion Inhibitory Peptide Targeting the MERS-CoV S2 Protein HR1 Domain and a Neutralizing Antibody Specific for the S1 Protein Receptor-Binding Domain (RBD) Showed Potent Synergism against Pseudotyped MERS-CoV with or without Mutations in RBD.
Viruses. 2019 Jan 6;11(1):31. doi: 10.3390/v11010031.
4
Enfuvirtide (T20)-Based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implications for Viral Entry and Inhibition.
J Virol. 2017 Aug 24;91(18). doi: 10.1128/JVI.00831-17. Print 2017 Sep 15.
5
Peptides corresponding to the predicted heptad repeat 2 domain of the feline coronavirus spike protein are potent inhibitors of viral infection.
PLoS One. 2013 Dec 3;8(12):e82081. doi: 10.1371/journal.pone.0082081. eCollection 2013.
6
Effect of amphipathic HIV fusion inhibitor peptides on POPC and POPC/cholesterol membrane properties: a molecular simulation study.
Int J Mol Sci. 2013 Jul 15;14(7):14724-43. doi: 10.3390/ijms140714724.
7
Closing the door to human immunodeficiency virus.
Protein Cell. 2013 Feb;4(2):86-102. doi: 10.1007/s13238-012-2111-9. Epub 2013 Mar 12.
8
Approaches for identification of HIV-1 entry inhibitors targeting gp41 pocket.
Viruses. 2013 Jan 11;5(1):127-49. doi: 10.3390/v5010127.
9
Interactions between different generation HIV-1 fusion inhibitors and the putative mechanism underlying the synergistic anti-HIV-1 effect resulting from their combination.
FASEB J. 2012 Mar;26(3):1018-26. doi: 10.1096/fj.11-195289. Epub 2011 Nov 15.
10
Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design.
Curr Top Med Chem. 2011 Dec;11(24):2959-84. doi: 10.2174/156802611798808497.
本文引用的文献
1
Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor.
J Biol Chem. 2008 Apr 25;283(17):11126-34. doi: 10.1074/jbc.M800200200. Epub 2008 Feb 26.
2
Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies.
Pharmacol Rev. 2006 Sep;58(3):621-81. doi: 10.1124/pr.58.3.10.
3
Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis.
J Acquir Immune Defic Syndr. 2006 Sep;43(1):60-4. doi: 10.1097/01.qai.0000234083.34161.55.
4
Pharmacokinetics of sifuvirtide, a novel anti-HIV-1 peptide, in monkeys and its inhibitory concentration in vitro.
Acta Pharmacol Sin. 2005 Oct;26(10):1274-80. doi: 10.1111/j.1745-7254.2005.00163.x.
5
Combination of candidate microbicides cellulose acetate 1,2-benzenedicarboxylate and UC781 has synergistic and complementary effects against human immunodeficiency virus type 1 infection.
Antimicrob Agents Chemother. 2005 May;49(5):1830-6. doi: 10.1128/AAC.49.5.1830-1836.2005.
6
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
N Engl J Med. 2003 May 29;348(22):2175-85. doi: 10.1056/NEJMoa035026. Epub 2003 Mar 13.
7
HIV-1 inhibition by a peptide.
Nature. 1993 Sep 9;365(6442):113. doi: 10.1038/365113a0.
8
Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.
Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9770-4. doi: 10.1073/pnas.91.21.9770.
Zotero 插件